HUTCHMED Announces Appointment of Acting Chief Executive Officer

Core Viewpoint - HUTCHMED announces the temporary leave of its CEO Dr. Weiguo Su due to health reasons, with CFO Johnny Cheng appointed as Acting CEO to ensure continuity in operations and strategy execution [1][2]. Company Leadership Changes - Dr. Weiguo Su, the Executive Director and CEO, is taking a leave of absence for health reasons, emphasizing the need to focus on his recovery [1][2]. - Johnny Cheng, currently the Executive Director and CFO, has been appointed as Acting CEO, effective immediately, while continuing his role as CFO [1][2]. Board Support and Confidence - The Board of Directors expresses full support for Dr. Su and confidence in Mr. Cheng's capabilities to manage the company during this interim period [2]. - The Board reassures stakeholders that all research, development, and commercial initiatives will remain on track despite the leadership change [2]. Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [3]. - The company has successfully marketed its first three medicines in China, with the first also approved in global markets including the US, Europe, and Japan [3].